Oxaliplatin-induced increase in splenic volume; irreversible change after adjuvant FOLFOX.
Takuma IwaiTakeshi YamadaMichihiro KoizumiSeiichi ShinjiYasuyuki YokoyamaGoro TakahashiKohki TakedaKeisuke HaraKeiichiro OhtaEiji UchidaPublished in: Journal of surgical oncology (2017)
SV increased after adjuvant mFOLFOX6, and had not recovered in almost half of cases 1-year after finishing chemotherapy. This increase may indicate continuous SOS, which can adversely affect treatment after recurrence.